Home » Industry Keynote: Sepsis Tech and Innovation
Industry Keynote: Sepsis Tech and Innovation
Breaking New Ground in Sepsis Diagnosis and Management with Non-Culture-Based Tests
The presentation discusses the current challenges in detecting sepsis-causing pathogens and how the use of non-culture-based-tests like T2Bacteria and T2Candida provide faster and more accurate results than the current standard of care, which relies on a positive blood culture.1
Speakers: Dr. Debra Goff, PharmD, FCCP, from The Ohio State University Wexner Medical Center and Dr. Aparna Ahuja, the Chief Medical Officer of T2 Biosystems
1. Nguyen, M. H., et al. Performance of the T2Bacteria Panel for Diagnosing Bloodstream Infections. A Diagnostic Accuracy Study. Annals of Internal Medicine. 2019.
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.